The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
about
Quantification of HER family receptors in breast cancerHigh EGFR_1 Inside-Out Activated Inflammation-Induced Motility through SLC2A1-CCNB2-HMMR-KIF11-NUSAP1-PRC1-UBE2C.The heterogeneous landscape of ALK negative ALCL.Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.Time-domain microfluidic fluorescence lifetime flow cytometry for high-throughput Förster resonance energy transfer screening.ERBB4 is over-expressed in human colon cancer and enhances cellular transformationNeuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptakeFeedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.The Epidermal Growth Factor Receptor Forms Location-Dependent Complexes in Resting Cells.Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma.Analysis of Epidermal Growth Factor Receptor-Induced Cell Motility by Wound Healing Assay.HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.
P2860
Q27015506-9CC50E92-63B1-4F00-8D95-EF6985F581B6Q30651265-33E859FC-B743-4181-AB14-C2FA829B10DEQ33567012-13F09575-4FDA-4D65-A8F1-5F51748DB63BQ35221485-7B012BB6-79B4-4C2F-9A95-9881DB3CFCBEQ35530090-B230314B-F456-40F7-969B-5F161CD50237Q36067899-7CD4434F-FF4B-4A9C-AD2B-738868DE62F4Q36337964-81972724-09A0-4E64-9162-7E2F7E6A13E3Q37706176-99F8566F-8587-47C6-90ED-F2220D216FB1Q38730843-CDC66720-1A63-4DAE-AF4D-42F88F91A84CQ38770505-4FC551F2-B983-46A0-8BA5-DFDDA0EC4082Q43912153-342419BB-7DB1-4D2C-BC79-5C6D5BCF9C20Q50507053-F28F7CA8-22CA-4A6A-8A75-8E4806346A1FQ52608458-EEAEF93E-2243-44D9-AA4D-4BB150199D97
P2860
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@ast
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@en
type
label
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@ast
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@en
prefLabel
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@ast
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@en
P2093
P2860
P50
P1433
P1476
The ErbB4 CYT2 variant protect ...... enhance cancer cell motility.
@en
P2093
Andrew Tutt
Brian Burford
Cheryl E Gillett
Daniel R Matthews
Elena Ortiz-Zapater
Emanuele de Rinaldis
George Santis
James Monypenny
Jody Barbeau
Katherine Lawler
P2860
P356
10.1126/SCISIGNAL.2005157
P50
P577
2014-08-19T00:00:00Z